Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Personalized Dosing and Telehealth Support One of the biggest advantages of working with a platform like us is the personalized nature of the treatment
Rare side effects may include allergic reactions, skin rashes, or stomach upset
This robust pipeline includes drugs that not only target diabetes but also address obesity, recognizing the close link between the two conditions
Another SHE Media member, Gina Vaynshteyn (AVP, Commerce), also started a GLP-1 program postpartum
Amylin/Calcitonin Receptor Agonism (cagrilintide) Delays gastric emptying, reduces postprandial glucagon, and strongly promotes satiety Modulates appetite-regulating centers in the hindbrain, hypothalamus, and brain reward circuits, directly influencing food intake and choice May transiently activate the renin-angiotensin-aldosterone system with dose escalation, but without blood pressure or electrolyte derangements GLP-1 Receptor Agonism (semaglutide) Stimulates glucose-dependent insulin secretion and suppresses glucagon release to improve glycemic control Reduces appetite and ad libitum energy intake, with central effects on GLP-1R-expressing nuclei in hypothalamus and brainstem Delays gastric emptying and increases satiety, contributing to progressive bodyweight loss Pharmacokinetic Profile Route of Administration Subcutaneous Dosing Frequency Once weekly Route of Administration : Subcutaneous Injection Dosing Frequency: Once weekly Half -life: Cagrilintide: 7-8 days
